This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Award-Winning Healthcare Analytics Company, DiagnosisOne, Joins Alere Family

LOWELL, Mass., Oct. 22, 2012 /PRNewswire/ -- Clinical decision support (CDS) and analytics company, DiagnosisOne, recently joined the Alere family in July and is pleased to announce that it has been recognized by Black Book Rankings as the leading CDS vendor for Accountable Care Organizations (ACOs).

In August, Black Book Rankings reported client experience and customer satisfaction scores from organizations that participated in a survey to determine the top CDS solution vendor for ACOs. More than 2,800 CDS users were polled, the largest number to date, and 42 vendors were evaluated on the basis of 18 key performance indicators. DiagnosisOne received the highest scores and was identified as the leading CDS provider to ACOs.

"We are honored to be recognized as the leading CDS vendor for ACOs," said Mansoor Khan, Sc.D., CEO of DiagnosisOne. "We are also proud to join the Alere family and have access to broader resources that will advance our decision support and analytics solutions.  DiagnosisOne remains focused on enabling customers to make the most informed, evidence-based decisions in real time, at the point of care and beyond."

The company provides end-to-end CDS capabilities that automatically make patient information from disparate systems accessible to a provider, along with a configurable collection of more than 25,000 actionable clinical alert observations and analytics.  Its standards-based, turnkey solutions are fully configurable to each organization's specific needs with minimal effort, and they have been successfully deployed for hospital systems, multi-million member insurers, state and national governments, and leading electronic medical record vendors and systems integrators.

DiagnosisOne will continue to operate as an independent subsidiary of Alere, a leading provider of near-patient diagnostics and monitoring services, and its seasoned management team will remain intact.  The company is currently seeking healthcare IT talent to support growing R&D efforts at its Lowell facility.  

About DiagnosisOne

DiagnosisOne provides the healthcare industry with an unparalleled breadth and depth of analytics and clinical decision support solutions based on a single platform. Leveraging the world's largest library of evidence-based medical knowledge, DiagnosisOne's standards-based solutions integrate seamlessly with existing hospital and laboratory information systems to deliver actionable information that results in better patient care, reduced errors and better clinical outcomes. DiagnosisOne's customers include healthcare providers, payers, EMR companies, systems integrators and government entities, including the Centers for Disease Control (CDC), Massachusetts Department of Public Health and Blue Cross Blue Shield. Based in Lowell, Mass., DiagnosisOne was formed in 2003 by a team of physicians and healthcare IT professionals. In July 2012, DiagnosisOne joined Alere (NYSE: ALR), a leading provider of near-patient diagnostics and monitoring services, where it will operate as an independent subsidiary.  For more information, visit www.DiagnosisOne.com.

Erin Zwirn Schwartz MSL for DiagnosisOne781-684-0770 DiagnosisOne@schwartzmsl.com

SOURCE DiagnosisOne

Stock quotes in this article: ALR 
Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs